Innovative Research on C-Myc Inhibitors: Meet Nakul Balaji

Introduction to Nakul Balaji’s Research

Meet Nakul Balaji, a dedicated senior at Florida Atlantic University High School, whose groundbreaking research focuses on one of the most formidable drivers of cancer: the c-myc oncogene. Discovered to be dysregulated in over half of all cancer cases, c-myc plays a pivotal role in accelerating tumor growth while simultaneously compromising immune defense mechanisms. Balaji's work emphasizes the importance of identifying critical therapeutic targets within the realm of oncology.

Targeting C-Myc with Novel Inhibitors

Nakul Balaji's project, titled "Novel Small Molecule C-Myc Inhibitors for Cancer," aims to design specific inhibitors that can effectively disrupt the activity of this proto-oncogene. Using advanced methodologies, Balaji has employed PocketVEC—a machine learning tool designed to facilitate the discovery of RNA binding pockets. By analyzing these specific regions, he has been able to create a fragment library of small molecules that may provide new therapeutic avenues for inhibiting c-myc.

Innovative Screening Techniques

The screening process incorporates the use of diazirine and alkyne groups to create crosslinkable molecules that interact with c-myc mRNA. This innovative strategy not only enhances the understanding of the oncogene's binding interactions but also allows for visualization through the tagging of molecules with the TAMRA fluorophore. Subsequent validation of this binding process is conducted via gel electrophoresis and bioimaging, where Balaji and his team observed clear dose-response relationships, affirming the potential efficacy of the developed inhibitors.

As Balaji's research progresses, the implications of effectively targeting c-myc could revolutionize how oncologists approach cancer treatment strategies. By designing specific small molecule inhibitors, Nakul Balaji is positioning himself at the forefront of cancer research and therapeutic development, representing a significant step forward in addressing one of the most challenging aspects of tumor biology.